Business
Update on Strategic Review and Formal Sale Process
Update on Strategic Review and Formal Sale Process.
About this update from Aptamer Group Plc
[{"type":"text","content":"\n\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.\n \n \nFOR IMMEDIATE RELEASE\n \n31 July 2023\n \nAptamer Group plc\n \n(\"Aptamer Group\", \"APTA\" or the \"Company\")\n \nUpdate on Strategic Review and Formal Sale Process\n \nAptamer Group (AIM:APTA), the developer of novel Optimer® binds to enable innovation in the life sciences industry, provides an update regarding the Strategic Review and Formal Sale Process announced on 26 July 2023.\nEarlier today, the Company announced a conditional fundraising of £3.6 million. Accordingly, the board has decided to terminate the Formal Sale Process under the City Code on Takeovers and Mergers (the \"Takeover Code\"). The Company is not in discussions with any party in relation to a sale and is not in receipt of any approaches. Accordingly, the Company is no longer in an offer period and the requirement to make disclosures under Rule 8 of the Takeover Code has now ceased.\nFor further information, please contact:\n \n\n\n\nAptamer Group plc\nDr Rob Quinn\n \n\n\n+44 (0) 1904 217 404\n\n\n\n\nSPARK Advisory Partners Limited - Nominated and Financial Adviser\nAndrew Emmott / Mark Brady / Adam Dawes\n \n\n\n+44 (0) 20 3368 3550\n\n\n\n\nFRP Advisory Trading Limited - Financial Adviser\nMiles Needham\n \n\n\n+44 (0) 1727 811 111\n\n\n\n \nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018.\nAbout Aptamer Group plc\nAptamer develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.\nOptimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over $170 billion. Optimer binders are engineered to address many of the issu...